Millions of people with overactive bladder syndrome are prescribed daily anticholinergics. But research has linked these ...

Overactive Bladder Treatment market in terms of revenue was estimated to be worth $3.5 billion in 2022 and is poised to reach ...

Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

When this happens, symptoms associated with overactive bladder are reduced. Medications that fall under the beta-3 adrenergic agonists class of drugs are Myrbetriq (mirabegron) and Gemtesa (vibegron).

The symptoms may be temporary or chronic. Temporary overactive bladder symptoms are often a result of medication side effects or urinary tract infections (UTIs). These symptoms typically resolve ...

Sunobinop tosylate is under clinical development by Imbrium Therapeutics and currently in Phase I for Overactive Bladder.

The standard treatments for overactive bladder include lifestyle changes, bladder training, pelvic floor muscle training and anticholinergic (anti-muscarinic) drugs. Additional treatments for some ...

For the first time in over 25 years (since the approval of oxybutynin in 1972), better medications are available for the overactive bladder. With the recent approval of tolterodine and oxybutynin ...

In women, causes of overactive bladder are varied, but the common consequence, beyond the physical manifestations, are frustration and embarrassment. While medications designed to relax the bladder ...

MEDICATIONS taken by thousands of Brits for to treat an overactive bladder have been linked to dementia in a new study. Some forms of the medication have been found to raise the risk of dementia ...